entity

GM_CSF

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about GM_CSF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections
0Hypotheses
1Analyses
2Outgoing
1Incoming
0Experiments
1Debates

No AI portrait yet

Wiki Pages (5)

Knowledge base pages for this entity

GM-CSF Sargramostim Phase 2 (NCT04902703) - AD Immunotherapy

trial · 1940 words

GM-CSF Receptor Alpha Chain

protein · 1580 words

GM-CSF Receptor Common Beta Chain

protein · 1526 words

CSF2 — Colony Stimulating Factor 2 (GM-CSF)

gene · 1300 words

Sargramostim (GM-CSF) ALS Trial

clinical · 916 words

Outgoing (2)

TargetRelationTypeStr
microglial_activationactivatesphenotype0.70
MONOCYTESactivatescell_type0.56

Incoming (1)

SourceRelationTypeStr
LACCERregulatesprotein0.64

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

How do neurodegeneration gene expression patterns in SEA-AD differ from other po

neurodegeneration | 2026-04-04 | 8 hypotheses Top: 0.564

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (1)

Multi-agent debates referencing this entity

How do neurodegeneration gene expression patterns in SEA-AD differ from other po

closed · Rounds: 4 · Score: 0.94 · 2026-04-04

Related Research

Hypotheses and analyses mentioning GM_CSF in their description or question text

No additional research found